Benitec Biopharma Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jerel A. Banks
- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3940 Trust Way Hayward CA United States of America 94545
- IPO Date
- Jun 24, 2014
- CIK
- 0001808898
- Website
- benitec.com
- Similar Companies
- Business
- Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, specializing in the development of novel genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) platform. This platform combines RNA interference with gene therapy to create treatments that enable sustained silencing of disease-causing genes following a single administration, while simultaneously delivering wildtype replacement genes to restore normal cellular function. Its core products and services focus on the development of silence and replace-based therapeutics for chronic and life-threatening genetically defined diseases, with its lead product candidate BB-301, an AAV-based gene therapy designed to treat oculopharyngeal muscular dystrophy (OPMD) by silencing the mutant gene while replacing it with a functional version. In recent developments, Benitec Biopharma reported positive interim results from its Phase 1b/2a clinical trial of BB-301, achieving a 100% responder rate in the first cohort, and received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for dysphagia associated with OPMD, which is expected to expedite its clinical development and regulatory review. The company also completed a $100 million equity financing in November 2025 to fund ongoing development programs. Additionally, Suvretta Capital Management significantly increased its investment holdings in Benitec during late 2024, reflecting strong investor confidence in the company’s genetic medicine technology and growth prospects. Benitec operates primarily in the biotechnology and pharmaceutical industry segments with a focus on genetic therapies targeting rare and underserved diseases. The company’s technology platform is designed to enable long-term gene silencing combined with gene replacement, with applications potentially extending beyond OPMD to other genetically defined conditions. Founded in 1997, Benitec continues to advance its pipeline and collaborate with strategic partners to accelerate the development and commercialization of its genetic medicine therapies globally.
Company News
Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving Average – Here’s Why
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Benitec Biopharma (BNTC) Projected to Release Quarterly Earnings on Monday
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
AWM Investment Company Inc. Acquires New Position in Benitec Biopharma Limited $BNTC
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 16,836 Shares
Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 50,000 Shares
Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?
Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Purchases 10,215 Shares of Stock
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering